Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABCHIX:BACTBS 63 EV-to-EBITDA is 13.24 as of Jul. 25, 2026, which is 65% below its 10-year median of 37.83. GuruFocus rates CHIX:BACTBS with a GF Score™ of 63/100 and a GF Value™ of kr243.41. The stock has 2 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Bactiguard Holding AB ranks better than 53.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bactiguard Holding AB's enterprise value is kr669.0 Mil.
Bactiguard Holding AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr50.5 Mil. Therefore, Bactiguard Holding AB's EV-to-EBITDA for today is 13.24.
The historical rank and industry rank for Bactiguard Holding AB's EV-to-EBITDA or its related term are showing as below:
CHIX:BACTBs'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1052.25 Med: 37.83 Max: 489.42
Current: 13.24
During the past 13 years, the highest EV-to-EBITDA of Bactiguard Holding AB was 489.42. The lowest was -1052.25. And the median was 37.83.
CHIX:BACTBs's EV-to-EBITDA is ranked better than 53.92% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs CHIX:BACTBs: 13.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bactiguard Holding AB (CHIX:BACTBs) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bactiguard Holding AB's PE Ratio (TTM) for today is calculated as:
Bactiguard Holding AB's share price for today is kr128.60.
Bactiguard Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Bactiguard Holding AB EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BACTBS vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's EV-to-EBITDA falls into.
Bactiguard Holding AB's current Enterprise Value is kr669.0 Mil.
Bactiguard Holding AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr50.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (CHIX:BACTBS) has a EV-to-EBITDA of 13.24 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bactiguard Holding AB. This is 65% below median its historical median of 37.83. According to the industry distribution chart, Bactiguard Holding AB ranks #235 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is Bactiguard Holding AB's EV-to-EBITDA too high?
Bactiguard Holding AB's current EV-to-EBITDA of 13.24 is 65% below median its 10-year median of 37.83. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.85. Bactiguard Holding AB's value of 13.24 is 4.4% below this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #235 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #235 out of 510 companies for EV-to-EBITDA. This puts Bactiguard Holding AB in the upper half of its industry. The industry median EV-to-EBITDA is 13.85. Bactiguard Holding AB's value of 13.24 is 4.4% below this benchmark. While the company's 10-year median is 37.83 vs. the industry median of 13.85, Bactiguard Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current EV-to-EBITDA of 13.24 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bactiguard Holding AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current EV-to-EBITDA is 13.24, which is 65% below median its own 10-year median of 37.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current EV-to-EBITDA of 13.24. The stock's GF Value™ is kr243.41, compared to a current price of kr128.60 — trading 47.2% below its estimated fair value. The current EV-to-EBITDA is 13.24, which is 65% below median its 10-year median of 37.83 and 4.4% below the Medical Devices & Instruments industry median of 13.85. Bactiguard Holding AB's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current EV-to-EBITDA is 13.24 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 47.2% below its estimated GF Value™ of kr243.41.
Key valuation signals for CHIX:BACTBS:
EV-to-EBITDA: 13.24 (65% below median its 10-year median of 37.83)
GF Value™: kr243.41 vs. price of kr128.60 (47.2% below fair value)
Industry Position: 4.4% below the Medical Devices & Instruments median (#235 of 510)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
63GF Score
Get the complete analysis for CHIX:BACTBS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
